Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|June 27, 2023

Break Through the Boundaries of Purity Analysis of Long Guiding RNAs for New CRISPR Gene Editing Systems

Author(s)SCIEX

Webinar Date/Time: Tue, Aug 1, 2023 11:00 AM EDT

Take control of the purity of your prime editing guide RNAs and overcome secondary structure formation with a solution that offers the highest levels of resolution separation and repeatability.

Register Free: https://www.biopharminternational.com/bp_w/gene-editing

Event Overview:

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

In this webinar, you will learn how to mitigate technical challenges by disrupting the hydrogen bonds in pegRNA molecules and maintaining their denatured state during analysis using a method based on capillary gel electrophoresis (CGE). This method offers high resolution and provides purity quantification of these large, synthetic oligonucleotides.


Key Learning Objectives
Learn how to:

  • Overcome high amounts of secondary structures of large pegRNAs for next-generation CRISPR/Cas9 gene editing approaches.
  • Determine purity of synthetic pegRNA with high-resolution separation of the full-length product from its impurities.
  • Achieve a high level of repeatability with a relative standard deviation (RSD) of <3%.

Who Should Attend
Scientists, Sr. Scientists, Lab Managers, Lab Directors

Speakers:

Ashley Jacobi
Senior Manager of Applications Development, Genomics Medicine Integrated DNA Technologies

Tingting Li
Manager, Cell and Gene Therapy Applications
SCIEX

Register Free: https://www.biopharminternational.com/bp_w/gene-editing


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.